leaderobot.com reports debut of Yuanhua Intelligent’s new HX product

leaderobot.com reported that Yuanhua Intelligent’s new HX product debuted at the 18th COA Academic Conference.

There are separate reports about HX being exhibited and a new product debut, while we have also published a separate article introducing Kunwu®. Distinguishing information by product name and checking intended uses and clinical track records against primary sources are prerequisites for medical institutions and others to assess where the devices fit.

In an article dated Nov. 11, we reported that Yuanhua Intelligent had exhibited its HX robotic arm orthopedic surgery system at the 9th China International Import Expo Yuanhua Intelligent exhibits HX orthopedic surgery robot at 9th Import Expo. By contrast, leaderobot.com reported in an article dated Nov. 14 that a new HX product debuted at the COA Academic Conference on Nov. 13. An exhibition and a new product debut are different events, and the succession of reports alone does not show that the product’s maturity or deployment has advanced. When reviewing the product lineup, HX should be distinguished from Kunwu®. On Sept. 14, we reported that Yuanhua Intelligent had introduced its Kunwu® full orthopedic surgery robot in Boao, describing its use in complex cases Yuanhua Intelligent introduces Kunwu® full orthopedic surgery robot’s handling of complex cases in Boao. Considered alongside the current report about HX, this underscores the importance of not treating systems with different names as the same device or as having the same capabilities when tracking the company’s product and technology announcements. Commonalities and differences between the products should be outlined only to the extent supported by primary sources. For assessing the industry implications, reports of a product debut should also be read separately from information indicating clinical use or regulatory approval. Medical institutions and competing companies need more than the existence of an announcement to make decisions; relevant factors include intended procedures, approval status, clinical data and actual use. However, the current reports do not substantiate any of these. The materials available for this report do not include primary sources such as official announcements or regulatory documents. Accordingly, definitive claims about HX’s specifications or clinical capabilities, or its relationship to Kunwu®, should be avoided. Yuanhua Intelligent’s official materials and regulatory information should be checked to verify each product’s intended uses and clinical positioning individually. See the original article for details of leaderobot.com’s reporting and its account.